Manju George, Scientific Director at PALTOWN Development Foundation, shared a post on LinkedIn:
“If you are a stage 4 colorectal cancer patient or caregiver
- and are interested in the new class of drugs that everyone is excited about: bispecific antibodies
- and you want to learn more about what they are,
- the currently open 1L (for newly diagnosed patients who haven’t yet started treatments)trials
- as well as bispecific antibody trials available for other lines of therapy,
Look no further!
Dr.Nicholas DeVito gave an excellent Colontown DocTalk explaining all of these and you can find the video here.
Please check out COLONTOWN University Lecture Hall for over 90 DocTalk videos covering all aspectes of the colorectal cancer disease experience!”
Nicholas DeVito, Assistant Professor of Medicine at the Division of Medical Oncology at Duke University, shared a post by Manju George on LinkedIn, adding:
“Thanks for having me Manju George and PALTOWN Development Foundation for this discussion on bispecific antibodies for colorectal cancer!”
Other articles about Colorectal Cancer on Oncodaily.